Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
NDRA 
ENDRA Life Sciences Inc (NDRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: NDRA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $30
1 Year Target Price $30
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.52% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.20M USD | Price to earnings Ratio 0.28 | 1Y Target Price 30 |
Price to earnings Ratio 0.28 | 1Y Target Price 30 | ||
Volume (30-day avg) 1 | Beta -0.33 | 52 Weeks Range 2.90 - 11.96 | Updated Date 12/9/2025 |
52 Weeks Range 2.90 - 11.96 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 19.52 |
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.25 | Actual -2.1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -101.97% | Return on Equity (TTM) -236.34% |
Valuation
Trailing PE 0.28 | Forward PE - | Enterprise Value 6683280 | Price to Sales(TTM) - |
Enterprise Value 6683280 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.11 | Shares Outstanding 1497095 | Shares Floating 1095533 |
Shares Outstanding 1497095 | Shares Floating 1095533 | ||
Percent Insiders 12.6 | Percent Institutions 11.07 |
Upturn AI SWOT
ENDRA Life Sciences Inc
Company Overview
History and Background
ENDRA Life Sciences Inc. was founded in 2007. It focuses on developing Thermo Acoustic Enhanced UltraSound (TAEUS) technology.
Core Business Areas
- TAEUS Technology: Development and commercialization of TAEUS, a technology that enhances ultrasound imaging to provide tissue characterization at the point of care.
Leadership and Structure
Francois Michelon is the CEO. The company has a board of directors and operates with a management team focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- TAEUS Liver System: Designed for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Market share is still emerging. Competitors include traditional biopsy and MRI-based methods for liver fat quantification.
Market Dynamics
Industry Overview
The medical imaging market is growing, with increasing demand for non-invasive diagnostic tools, particularly for liver disease assessment.
Positioning
ENDRA is positioning TAEUS as a cost-effective, non-invasive alternative to liver biopsy and expensive MRI procedures. They aim to fill a gap in the market for accessible point-of-care diagnostics.
Total Addressable Market (TAM)
The global NAFLD/NASH market is estimated in the billions. ENDRA aims to capture a portion of this TAM by offering a non-invasive alternative.
Upturn SWOT Analysis
Strengths
- Non-invasive technology
- Potential for point-of-care diagnostics
- Cost-effective alternative to biopsy and MRI
Weaknesses
- Limited commercial traction to date
- Dependence on regulatory approvals
- Relatively small company size and resources
Opportunities
- Growing prevalence of NAFLD/NASH
- Expansion into new clinical applications
- Partnerships with healthcare providers
Threats
- Competition from established imaging modalities
- Regulatory hurdles
- Slow adoption rates by clinicians
Competitors and Market Share
Key Competitors
- SIEMENS (SIE.DE)
- GE HEALTHCARE (GE)
- FUJIFILM (FUJIY)
- CANON MEDICAL (7751.T)
Competitive Landscape
ENDRA faces competition from large, established medical imaging companies. Its advantage lies in its non-invasive TAEUS technology, but it needs to demonstrate clinical and economic value.
Growth Trajectory and Initiatives
Historical Growth: Growth has been limited due to pre-commercial stage.
Future Projections: Future growth depends on successful commercialization of TAEUS and regulatory approvals.
Recent Initiatives: Focus on securing regulatory approvals and establishing partnerships with healthcare providers.
Summary
ENDRA Life Sciences is a development-stage company with promising non-invasive ultrasound technology, specifically TAEUS, for liver disease assessment. Its success hinges on securing regulatory approvals and successfully commercializing TAEUS to gain market traction. While the company has innovative technology, its limited resources and dependence on financing activities pose challenges. Investors should closely monitor regulatory milestones, commercial partnerships, and financial performance to gauge ENDRA's prospects.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Analyst reports (where available)
- SEC filings (where available)
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated. Financial data and market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ENDRA Life Sciences Inc
Exchange NASDAQ | Headquaters Ann Arbor, MI, United States | ||
IPO Launch date 2017-05-09 | CEO & Chairman Mr. Alexander Y. Tokman | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 21 | Website https://endrainc.com |
Full time employees 21 | Website https://endrainc.com | ||
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.